Breaking News

Sartorius, Lonza in Cell Culture Media Collaboration

December 19, 2012

Products will be sold under a co-branding arrangement

Sartorius Stedim Biotech (SSB) has entered a global collaboration agreement with Lonza, expanding its product array of cell culture media for biopharma manufacturing processes.
 
SSB will assume global sales and marketing of Lonza’s media and buffers used in the manufacture of protein-based therapeutics and vaccines, and Lonza will continue provide development, manufacture and logistics operations for these products. The cell culture media, sold in liquid or powder form, will be converted to packaged forms as ready-to-use, prefilled SSB sterile single-use bags. The products will be sold under both brands in a co-branding arrangement.
 
“I am very pleased that we will now be adding a market-leading, high-quality array of media and buffers to our product offering,” said SSB’s member of the board, Reinhard Vogt. “Just like our single-use bags and bioreactors, culture media are critical to the success of safe and efficient manufacture of drug materials. The demand for ready-to-use and innovative products is accordingly high. In the manufacture of biologicals, our customers will benefit from obtaining fully integrated single-use solutions for their entire cell culture process all from a single source.”
 
“For Lonza this agreement provides great upside potential as it will allow us to capture additional value from our Media Business in the form of additional revenue leading to higher capacity utilization,” said Lukas Utiger, chief operating officer of Lonza Bioscience. “Lonza and Sartorius are a great fit as both partners bring complementary strengths to the benefit of our customers.”

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks